Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...I miss the board more than I do LBSR.
Agreed! (a_greedy JB)
Perhaps, but it's a PROVEN resource (selling for a pittance) and land route now chosen. They will partner or be bought out.
LBSR does have those merits and will be excellent once something proven (drill a damn hole)!
yes, both, and the holy hope of repeating that amazing 1000%+ run! JB is a great geologist, I have no doubt, but was a poor CEO. I never could understand why he/we couldn't partner those claims for development.
Fellas, thank you very much --very sad for LBSR and excellent for NAK. I may be back, but the prospects for NAK are just too good right now! Probably many current investors in NAK don't know about those scalped excellent LBSR claims.
BTW, I lost a fortune on LBSR...
GLTA
PS: who got those uranium claims?
sorry to bother anyone again, but just was hoping someone could point me to where we sold/lost all the circa-Pebble claims?
I've moved my mining money to NAK --sorry lost too much here following JB hype all those wasted years!
GLTA
and
TIA
Haven't been here in years --sad to see the state of affairs (9/100 of penny as PPS). Lost a lot of $ on LBSR. Trying to make it back with NAK. Does LBSR still hold on to the claims around Pebble?
TIA
https://www.sandiegouniontribune.com/news/science/story/2020-04-03/scripps-research-find-evidence-of-an-anchilles-heel
This research supports our thesis that what worked for SARS probably will work for COVID.
AIM higher!
I'm sorry --who is FG and GM?
TIA
This is absolutely a promising news release! The possibility of further trials in other countries, besides China and Japan, is very bullish!!
AIM higher
Yes!
We learned from our mistakes with zika --IBIO will help correct that.
I buy IBIO!!
We already have approval in Argentina (for CFS), but I wonder if CEO has been discussing with them to use for Covid?
AIM higher
Yes! You've nailed what this does --of those components, I've been taking astaxanthin for about a year (by itself) for glaucoma prevention. No side effects that I can discern.
Go GHSI!
how long does #CODX# test take?
I suppose it depends on preliminary vs final, but given how quickly one might perish from the illness --less than one month!?
I believe we'll hear about other countries participating before clinical results come.
What are your predictions?
From another board:
Allow usage here!
From another board:
And what about arguing for “compassionate care usage” with our FDA?
Did Equels say that he was approaching FDA/US govt about using Ampligen here for Covid?
Wow! Thank you for sharing. That absolutely should put a floor under the stock. Now way undervalued, assuming that the oil war between Saudi and Russia doesn't drag out. Also, quite possible we and 2 are strategic petroleum reserve! Another possibility, is we put a tariff on Saudi and Russian oil.
Can someone print an AH chart for today please?
TIA
Let's not forget we may see news of our countries entering trials with our Ampligen!?
AIM higher!
Registered with the SEC.
Not our company, but highly relevant!!
Mallinckrodt Evaluates Inhaled Nitric Oxide for Covid-19 Lung Complications MNK
7:22 AM ET 3/12/20 | Dow Jones
Related Quotes
6:30 PM ET 3/11/20
Symbol Last % Chg
MNK
3.05 0.00%
Real time quote.
By Colin Kellaher
Mallinckrodt PLC on Thursday said it is evaluating the potential role for inhaled nitric oxide to treat pulmonary complications associated with the novel coronavirus.
The U.K.-based biopharmaceutical company said it has engaged with the U.S. Food and Drug Administration, the National Institutes of Health and the Biomedical Advanced Research and Development Authority on the matter.
Mallinckrodt, which markets inhaled nitric oxide in the U.S. as INOmax for neonates with hypoxic respiratory failure associated with pulmonary hypertension, said the safety and efficacy for pulmonary complications associated with the novel coronavirus haven't been established.
However, the company said that while nitric oxide hasn't been specifically studied or used to treat Covid-19, it has shown an in-vitro inhibitory effect on the replication cycle of severe acute respiratory syndrome-related coronavirus, or SARS, which left hundreds dead during the 2003 outbreak.
Write to Colin Kellaher at colin.kellaher@wsj.com
> Dow Jones Newswires
March 12, 2020 07:22 ET (11:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Director John Palmour just bought 200k shares
Of course before the price war commenced.
Another runner in the works!
Good story to piggy-back on COVID plays.
Having an immediately available treatment option is huge! People are dying, help wanted!
Analogous to why $AIM$ ran so much today, and immediately available treatment.
I was able to sneak in at 0.48. Interestingly, I had to call my broker, Etrade, to get it filled. I had to raise my bid price while the broker got the order squared away...
I think it's worthwhile pointing out why it cratered in early Jan --if better powered, the study would have probably been statistically significant and why they wanted to continue trialing it.
looks like recently, every forth trading day is a bump!?
up big in pre-mkt
500k share order just went thru
Wow! Nice action.
I think the last video was MUCH better than the earlier one. Good emphasis on the NOW with COVID-19 application. Convenient way to also get the word out on multiple cancer trials.
Also new: he mentioned talks with Japan> Europe.
AIM higher!
Who is the supplier of "additional resources to scale up"?
https://www.marketwatch.com/story/inovio-shares-rally-after-biotech-says-human-trials-of-coronavirus-vaccine-will-start-in-april-2020-03-03
Diagnostic companies are take-out targets (see below). Go OPGN!
__________________
Thermo Fisher to Buy Qiagen in $10.1 Billion Deal
4:29 AM ET 3/3/20 | Dow Jones
By Adria Calatayud
Thermo Fisher Scientific Inc. said Tuesday that it has agreed to acquire Frankfurt-listed provider of molecular diagnostics Qiagen NV in a deal that values the target at around $10.1 billion.
Thermo Fisher said its proposal values each Qiagen share at 39 euros ($43.30) in cash, representing a premium of around 23% to Monday's closing price. Including debt of $1.4 billion, the deal is worth $11.5 billion, Thermo Fisher said.
Waltham, Massachusetts-based Thermo Fisher, a provider of analytical instruments and equipment for research, analysis, discovery, and diagnostics, said the acquisition of Qiagen, which is based in Venlo, the Netherlands, is expected to be immediately accretive to adjusted earnings per share after close. The deal will expand Thermo Fisher's specialty diagnostics portfolio and complement its life-sciences offering, the company said.
This part (see below) of the PR should be better emphasized by our CEO. Yes, in the TV interview, he rightly also draws attention to the long-term prospects of Ampligen with cancer therapeutics. But I think he could better tout the short-term potential to save lives in those infected with COVID-19. This is also personal for me as a physician on the frontlines in US.
With you, Rich!
Stopped following this board, but remain invested.
GO LBSR!!
Papermaker, LIKE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
GO SUPER LBSR!!